Investors were hoping for a partnership after ASCO last year. Investors were hoping for a partnership in December of last year. Investors will be hoping for a partnership after ASCO this year.
The problem with ONCS is that big pharma will NOT offer a partnership until efficacy with electroporation is proven in a P2 COMBINATION trial. That's what the P2B trial with Keytruda is all about. And that's why it's so important to the company to get it started!
This was originally promised in December, then in Q1, and now "sometime" in Q2. That's why you're seeing the sell-off this week. It has nothing to do with "manipulation." It has everything to do with frustrated investors who are tired of being promised dates only to see them pass with no results.
And when I say PARTNERSHIP, I mean one where there is up-front money paid, milestone payments, and a REGULATORY PATH laid out with a partner. ONCS has NONE of that. But that is the hope. But again, big pharma will not offer this type of deal until the P2B trial is completed later in 2016, or at a minimum, when interim data is available later this year. (IF it is made available.) But there will be NO DATA until the trial is started!!!
Others have told me that I'm thinking too far ahead. But I beg to differ. The market has spoken and is showing how important the P2B trial actually is to the company and to its investors.
Get it going, ONCS!
Yes, a temporary pop only, but at least a pop.
But what else do they really have. No real data releases of note until 2016.
The pivotal P2B trial is the most important in the company's history.
Why wouldn't starting it be a catalyst?
Yes. Enrollment will begin "sometime" in Q2 now.
It was originally scheduled for Q1.
Frankly, I'd love it if ADXS bought them. (Or anyone, for that matter.)
Avtar Dhillon (Punit's rich uncle) has never brought a product to market. Just look at his background. It's all available online. He has been good at dilution and taking advantage of capital markets for his own personal gain, however.
Punit, for his part, is trying. But he suffers from poor communication skills and historically over-promises and under-delivers. He's even done that at a personal level with a few investors on this board. And he also has a history of dilution. Maybe it's built into his DNA.
I sold all of my remaining shares within 45 seconds after Punit mentioned that there would be a delay in enrolling patients for their pivotal P2B combination trial. Without that trial getting on the move, they have very little to offer.
To be honest, I had a strong sense that was coming during the conference call, and already had the trading section of my brokerage account open and ready.
I repeat, the science is great, the management most assuredly is NOT. Please, someone buy this company. Cancer patients can be helped, but not if management moves at a snails pace.
This is a nice floor, but there is not nearly enough volume for "capitulation" in a classic sense.
It's been awhile since I've look at this message board.
You're now a convicted 1st degree PUMPER. Confirmed!
IF, as you say, it's a "long-term" development ($3.3M) why would the shorts need to cover so quickly? (As in "tomorrow.")
I have to admit, you DO make me chuckle at times.
I agree with you on that. But I will say this. It's very unlikely. One has to go with the best odds with the best information which is available.
Can you tell me (with information available now) of any specific catalysts in 2015 which will first move the PPS substantially higher than 0.50 and then sustain it there for more than 5 minutes? (Note: ONCS reached a high of 0.97 last year, but that's a bit misleading. It held that level for less than 5 minutes.)
He really needs to learn how to manage expectations better.
Most of of here work or have worked in the business world. That's one of the easiest ways to lose credibility.
Long live the ONCS science!
It's probably better that you leave.
You're deceiving people if you suggest that P2B results will be known this year.
It's clear you didn't listen to conference call today and that you know very little about this company then.
I don't call people names. Only morons do.
Why should I leave? No reason to.
P2B results won't be known until sometime in 2016, correct?
What big pharma will buy ONCS without P2B combination data?
Monotherapies rarely get bought out now. Maybe a year ago, but not now.
Apropos for today.